Robert Gordon, MD
Pulmonary Disease · Oklahoma City, OKNPI 1093701658
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $783 of the $1,038 with a category attached, or 75.4%. Janssen Research & Development, LLC accounts for 97.4% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $1,011 and has fallen 98.7% since, to $13 in 2023. That places this record below the midpoint for pulmonary disease clinicians in OK, where the typical reported total is $1,778.
Across 12 payments — averaging $86.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$1K
- AstraZeneca$14
- Inspire Medical Systems, Inc.$13
Across 76 payments — averaging $2372.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$48K
- Ironwood Pharmaceuticals, Inc$40K
- Janssen Research & Development, LLC$29K
- Teva Pharmaceuticals USA, Inc.$24K
- Pfizer$22K
- Eli Lilly$11K
- plus $7K from 2 others
What the payments were for
- Travel & lodging$78375%
- Food & beverage$25525%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 10 | $1,011 |
| AstraZeneca | 1 | $14 |
| Inspire Medical Systems, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$783
How this compares
$1,038 in reported general payments places this provider in the 35th percentile of 133 pulmonary disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $28,080 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $18,060 |
| Spiriva RespimatTiotropium Bromide | 16 | $10,062 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $6,240 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $5,322 |
| Montelukast Sodium | 119 | $1,559 |
| Zafirlukast | 12 | $977 |
| Theophylline ErTheophylline Anhydrous | 13 | $888 |
| Zolpidem Tartrate | 46 | $598 |
| Gabapentin | 19 | $559 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $507 |
| Ropinirole Hcl | 28 | $506 |
| Zolpidem Tartrate ErZolpidem Tartrate | 13 | $503 |
| Armodafinil | 13 | $456 |
| Clonazepam | 52 | $352 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSymbicort | $14 | $5,32225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 133 pulmonary disease providers in Oklahoma.
Other pulmonary disease in Oklahoma City
- John KingreyOklahoma City$332K
- Fawad ChaudryOklahoma City$80K
- Maroun TawkOklahoma City$62K
- Nathaniel MoultonOklahoma City$28K
- Syed NaqviOklahoma City$15K
- Tarek DernaikaOklahoma City$12K
- Shoab NazirOklahoma City$11K
- Mark GodishOklahoma City$11K
- Mazen ZouwayhedOklahoma City$10K
- Shoaib AhmadOklahoma City$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.